secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001493152-26-014129
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates
--------------------------------------------------------------------------------

- Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.
- Cash at $11.9M, down from $29.7M; adjusted EBITDA loss improved to $28.0M from $33.5M.
- Received CDSCO license for PCR Pro instrument in India; expanding to South Asia with $13B addressable market.
- Planning initial FDA 510(k) for flu A/B/RSV test, dropping COVID from initial submission to accelerate timeline.
- Closed stock offerings raising $10.8M; engaged Maxim Group for potential SPAC for CoSara.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/0001493152-26-014129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-014129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer